EUVIMEDEUVIMED entdecken
Crossref

Phase II Study of Ipilimumab, Nivolumab, and Panitumumab in Patients With KRAS / NRAS / BRAF Wild-Type Microsatellite Stable Metastatic Colorectal Cancer

Ashwin Somasundaram, Dominic T. Moore, Anita A. Turk, Iman Imanirad, Stacey A. Cohen, Kristen K. Ciombor, Tammy Triglianos, Autumn J. McRee, Michael S. Lee, Hanna K. Sanoff

JCO Oncology Advances · 2025-02 · (2)

DOI: 10.1200/oa-24-00086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2025-02. Verfasst von Ashwin Somasundaram und 9 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Panitumumab, a monoclonal antibody targeting epidermal growth factor receptor (EGFR), is standard therapy for patients with KRAS/NRAS/BRAF wild-type (WT), microsatellite stable (MSS), metastatic colorectal cancer (mCRC). We hypothesized that the addition of ipilimumab (anti–cytotoxic T-cell lymphocyte-4) and nivolumab (anti-PD1) to panitumumab would increase response rate. METHODS This is a phase II, multicenter, single-arm trial of panitumumab, ipilimumab, and nivolumab in KRAS / NRAS / BRAF WT, MSS mCRC. Eligible patients had received ≥1 previous lines of therapy and no previous anti-EGFR or immune checkpoint inhibitor. Patients received ipilimumab 1 mg/kg IV once every 6 weeks, nivolumab 240 mg IV once every 2 weeks, and panitumumab 6 mg/kg IV once every 2 weeks until progression, toxicity, or patient withdrawal. The primary outcome was overall response rate at 12 weeks. Using a Simon's two-stage design, with null and alternative hypothesis response rates of 22% and 35%, responses in ≥17 patients of 56 would be considered worthy of additional study. RESULTS In 56 patients enrolled between March 2018 and June 2020, the response rate was 32.1% (95% CI, 21.4 to 45.2; n = 18). The median progression-free survival was 6.0 months (95% CI, 5.5 to 7.4), and the median overall survival was 17.4 months (95% CI, 14.2 to 27.5). With a median follow-up of 43.3 months (95% CI, 41 to 55), four patients (10.7%) were alive without progression, including two patients with liver metastases. There was one treatment-related grade 5 myocarditis. The most common treatment-related grade 3 to 4 toxicities included lipase increased (9%), amylase increased (7%), ALT increased (5%), AST increased (5%), diarrhea (5%), hypophosphatemia (5%), and maculopapular rash (5%). CONCLUSION The combination of panitumumab, ipilimumab, and nivolumab demonstrated an acceptable response rate including a signal of durable response even among patients with liver metastases, suggesting activity of immune checkpoint inhibitors combined with anti-EGFR therapy in MSS mCRC.

Zitieren

APA

Somasundaram, A., Moore, D. T., Turk, A. A., Imanirad, I., Cohen, S. A., Ciombor, K. K., Triglianos, T., McRee, A. J., Lee, M. S., & Sanoff, H. K. (2025). Phase II Study of Ipilimumab, Nivolumab, and Panitumumab in Patients With KRAS / NRAS / BRAF Wild-Type Microsatellite Stable Metastatic Colorectal Cancer. JCO Oncology Advances. https://doi.org/10.1200/oa-24-00086

Vancouver

Somasundaram A, Moore DT, Turk AA, Imanirad I, Cohen SA, Ciombor KK, et al. Phase II Study of Ipilimumab, Nivolumab, and Panitumumab in Patients With KRAS / NRAS / BRAF Wild-Type Microsatellite Stable Metastatic Colorectal Cancer. JCO Oncology Advances. 2025. doi:10.1200/oa-24-00086

BibTeX
@article{Somasundaram2025,
  author = {Somasundaram, Ashwin and Moore, Dominic T. and Turk, Anita A. and Imanirad, Iman and Cohen, Stacey A. and Ciombor, Kristen K. and Triglianos, Tammy and McRee, Autumn J. and Lee, Michael S. and Sanoff, Hanna K.},
  title = {Phase II Study of Ipilimumab, Nivolumab, and Panitumumab in Patients With KRAS / NRAS / BRAF Wild-Type Microsatellite Stable Metastatic Colorectal Cancer},
  journal = {JCO Oncology Advances},
  year = {2025},
  number = {2},
  doi = {10.1200/oa-24-00086}
}
Kostenlos starten →